Previous 10 | Next 10 |
2023-08-11 11:19:08 ET Tarsus Pharmaceuticals press release ( NASDAQ: TARS ): Q2 GAAP EPS of -$1.17. For further details see: Tarsus Pharmaceuticals GAAP EPS of -$1.17
XDEMVY™ (lotilaner ophthalmic solution) 0.25% received FDA approval for the treatment for Demodex blepharitis On track to have XDEMVY and sales force in market by the end of August 2023 Completed enrollment of Galatea, a Phase 2a trial evaluating TP-04 for Rosacea, with t...
2023-08-02 05:50:42 ET Tarsus Pharmaceuticals ( NASDAQ: TARS ) prices underwritten offering of 5,714,285 shares at a public offering price of $17.50 per share. Underwriters have a 30-day option to purchase up to an additional 857,142 shares. Gross proceeds are expected...
IRVINE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye ca...
2023-07-31 17:11:02 ET Tarsus Pharmaceuticals ( NASDAQ: TARS ) has proposed to raise $100 million through an underwritten public offering of shares of its common stock, the company said Monday. The underwriters of the proposed offering have a 30-day option to purchase up...
IRVINE, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye ca...
2023-07-25 17:56:43 ET Summary Tarsus Pharmaceuticals, Inc. achieved FDA approval of XDEMVY for the treatment of patients with Demodex blepharitis; XDEMVY for this indication could offer $1 billion + peak net sales potential. Results from the phase 2 study using XDEMVY [TP-03] for...
2023-07-25 12:09:08 ET Gainers: Electra Battery Materials ( ELBM ) +72% . Bullfrog AI Holdings ( BFRG ) +38% . Kiniksa Pharmaceuticals ( KNSA ) +30% . Steakholder Foods ( STKH ) +25% . Galecto ( GLTO ) +23% . Rigetti Computin...
2023-07-25 11:17:07 ET Tarsus Pharmaceuticals ( NASDAQ: TARS ) announced Tuesday that the FDA greenlighted its lead asset TP-03 as a treatment for the eyelid disorder Demodex blepharitis. Demodex blepharitis affects approximately 25M eyecare patients in the U.S., with a prevalen...
2023-07-25 10:18:59 ET Gainers: Bullfrog AI ( BFRG ) +35% . Carmell Therapeutics ( CTCX ) +32% . Kiniksa Pharmaceuticals ( KNSA ) +21% . Galecto ( GLTO ) +18% . Akebia Therapeutics ( AKBA ) +16% . Losers: NeuroOne Med...
News, Short Squeeze, Breakout and More Instantly...
Tarsus Pharmaceuticals Inc. Company Name:
TARS Stock Symbol:
NASDAQ Market:
Tarsus Pharmaceuticals Inc. Website:
2024-06-03 08:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in t...
2024-05-13 07:00:04 ET Oren Livnat from H.C. Wainwright issued a price target of $61.00 for TARS on 2024-05-13 06:01:00. The adjusted price target was set to $61.00. At the time of the announcement, TARS was trading at $37. TARS currently trades -5.98% versus its 52 week...